You searched for "technological"
Pomegranate juice as an otoprotective agent
Chemotherapeutic agents such as cisplatin, given alongside irradiation, offer a survival advantage in head and neck cancer. Some patients often complain bitterly about side-effects of their treatment, one of which is ototoxicity. In this paper, the authors propose the use...
Long-term voice outcomes following transoral laser surgery versus radiotherapy for early laryngeal cancers
The oncological outcomes of transoral laser microsurgery (TOLM) for early laryngeal cancers are well-known to be very similar to radiation therapy (RT). The functional outcomes associated with each treatment modality are therefore of significant interest. This study is reported to...
Gastrostomy tube dependence following TORS
Transoral robotic surgery (TORS) for oropharyngeal squamous cell carcinoma (OPSCC) is now a well-established treatment modality for early (T1-T2) disease. Accumulating evidence suggests that one of its main benefits relative to conventional chemoradiotherapy is superior long-term functional outcome, especially with...Hunting for the zorse - hybrid learning in the wake of the COVID-19 pandemic
Emma Watts, a West Midlands ENT Registrar and Digital Fellow, gives a witty and concise recollection of ENT training during COVID, and predicts how hybrid learning may be here to stay. *A zorse is the offspring of a zebra stallion...
Preoperative planning of the surgical patient
This article covers the need to effectively optimise patient status preoperatively to help maximise postoperative outcomes. The article is well written and emphasises close liaison with anaesthetic colleagues particularly regarding airway assessment and nausea and vomiting. As is becoming common...Industry interaction with the ENT speciality
I was enormously grateful for the chance to articulate my personal thoughts on ‘the industry interaction with the ENT clinical community’. To set a context, the term ‘industry’ refers to medical technology manufacturers and suppliers, in addition to pharmaceutical companies....
